Xinyue Jiang, Clement C Zai, John Merranko, L Trevor Young, Boris Birmaher, Benjamin I Goldstein
{"title":"双相情感障碍青少年的精神病多基因风险评分和逐周症状状态:一项探索性研究。","authors":"Xinyue Jiang, Clement C Zai, John Merranko, L Trevor Young, Boris Birmaher, Benjamin I Goldstein","doi":"10.1089/cap.2024.0130","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> Prior studies have demonstrated that, in both adults and youth, bipolar disorder (BD) is a polygenic illness. However, no studies have examined polygenic risk scores (PRSs) in relation to the longitudinal course of mood symptoms in youth with BD. <b><i>Methods:</i></b> This study included 246 youth of European ancestry with BD (7-20 years old at intake) from the Course and Outcome of Bipolar Youth study and Centre for Youth Bipolar Disorder. Mood symptom severity was assessed at intake and, for 168 participants, prospectively for a median of 8.7 years. PRSs for BD, schizophrenia (SCZ), major depressive disorder (MDD), and attention-deficit/hyperactivity disorder (ADHD) were constructed using genome-wide summary statistics from independent adult cohorts. <b><i>Results:</i></b> Higher BD-PRS was significantly associated with lower most severe lifetime depression score at intake (<i>β</i> = -0.14, <i>p</i> = 0.03). Higher SCZ-PRS and MDD-PRS were associated with significantly less time spent in euthymia (SCZ-PRS: <i>β</i> = -0.21, <i>p</i> = 0.02; MDD-PRS: <i>β</i> = -0.22, <i>p</i> = 0.01) and more time with any subsyndromal mood symptoms (i.e., any mania, mixed, or depression symptoms; SCZ-PRS: <i>β</i> = 0.15, <i>p</i> = 0.04; MDD-PRS: <i>β</i> = 0.17, <i>p</i> = 0.01) during follow-up. PRSs for BD and ADHD were not significantly associated with any longitudinal mood variable. <b><i>Conclusions:</i></b> This exploratory analysis was the first to examine psychiatric PRSs in relation to the prospective course of mood symptoms among youth with BD. Results from the current study can serve to guide future youth BD studies with larger sample sizes on this topic.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Psychiatric Polygenic Risk Scores and Week-by-Week Symptomatic Status in Youth with Bipolar Disorder: An Exploratory Study.\",\"authors\":\"Xinyue Jiang, Clement C Zai, John Merranko, L Trevor Young, Boris Birmaher, Benjamin I Goldstein\",\"doi\":\"10.1089/cap.2024.0130\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Introduction:</i></b> Prior studies have demonstrated that, in both adults and youth, bipolar disorder (BD) is a polygenic illness. However, no studies have examined polygenic risk scores (PRSs) in relation to the longitudinal course of mood symptoms in youth with BD. <b><i>Methods:</i></b> This study included 246 youth of European ancestry with BD (7-20 years old at intake) from the Course and Outcome of Bipolar Youth study and Centre for Youth Bipolar Disorder. Mood symptom severity was assessed at intake and, for 168 participants, prospectively for a median of 8.7 years. PRSs for BD, schizophrenia (SCZ), major depressive disorder (MDD), and attention-deficit/hyperactivity disorder (ADHD) were constructed using genome-wide summary statistics from independent adult cohorts. <b><i>Results:</i></b> Higher BD-PRS was significantly associated with lower most severe lifetime depression score at intake (<i>β</i> = -0.14, <i>p</i> = 0.03). Higher SCZ-PRS and MDD-PRS were associated with significantly less time spent in euthymia (SCZ-PRS: <i>β</i> = -0.21, <i>p</i> = 0.02; MDD-PRS: <i>β</i> = -0.22, <i>p</i> = 0.01) and more time with any subsyndromal mood symptoms (i.e., any mania, mixed, or depression symptoms; SCZ-PRS: <i>β</i> = 0.15, <i>p</i> = 0.04; MDD-PRS: <i>β</i> = 0.17, <i>p</i> = 0.01) during follow-up. PRSs for BD and ADHD were not significantly associated with any longitudinal mood variable. <b><i>Conclusions:</i></b> This exploratory analysis was the first to examine psychiatric PRSs in relation to the prospective course of mood symptoms among youth with BD. Results from the current study can serve to guide future youth BD studies with larger sample sizes on this topic.</p>\",\"PeriodicalId\":15277,\"journal\":{\"name\":\"Journal of child and adolescent psychopharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-03-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of child and adolescent psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/cap.2024.0130\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of child and adolescent psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/cap.2024.0130","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
摘要
先前的研究表明,在成人和青少年中,双相情感障碍(BD)是一种多基因疾病。然而,没有研究检测多基因风险评分(PRSs)与双相障碍青年情绪症状纵向病程的关系。方法:本研究包括246名欧洲血统双相障碍青年(7-20岁),来自双相障碍青年研究和青年双相障碍中心的过程和结果。在摄入时对168名参与者的情绪症状严重程度进行评估,预期中位数为8.7年。使用独立成人队列的全基因组汇总统计构建双相障碍、精神分裂症(SCZ)、重度抑郁症(MDD)和注意缺陷/多动障碍(ADHD)的PRSs。结果:摄入时较高的BD-PRS与较低的最严重终生抑郁评分显著相关(β = -0.14, p = 0.03)。较高的SCZ-PRS和MDD-PRS与较短的精神状态时间相关(SCZ-PRS: β = -0.21, p = 0.02;MDD-PRS: β = -0.22, p = 0.01),出现任何亚综合征情绪症状(即任何躁狂症、混合性或抑郁症状;SCZ-PRS: β = 0.15, p = 0.04;MDD-PRS: β = 0.17, p = 0.01)。双相障碍和多动症的PRSs与任何纵向情绪变量均无显著相关。结论:这项探索性分析首次研究了精神病学PRSs与青年双相障碍患者情绪症状的前瞻性病程之间的关系。本研究的结果可以指导未来更大样本量的青年双相障碍研究。
Psychiatric Polygenic Risk Scores and Week-by-Week Symptomatic Status in Youth with Bipolar Disorder: An Exploratory Study.
Introduction: Prior studies have demonstrated that, in both adults and youth, bipolar disorder (BD) is a polygenic illness. However, no studies have examined polygenic risk scores (PRSs) in relation to the longitudinal course of mood symptoms in youth with BD. Methods: This study included 246 youth of European ancestry with BD (7-20 years old at intake) from the Course and Outcome of Bipolar Youth study and Centre for Youth Bipolar Disorder. Mood symptom severity was assessed at intake and, for 168 participants, prospectively for a median of 8.7 years. PRSs for BD, schizophrenia (SCZ), major depressive disorder (MDD), and attention-deficit/hyperactivity disorder (ADHD) were constructed using genome-wide summary statistics from independent adult cohorts. Results: Higher BD-PRS was significantly associated with lower most severe lifetime depression score at intake (β = -0.14, p = 0.03). Higher SCZ-PRS and MDD-PRS were associated with significantly less time spent in euthymia (SCZ-PRS: β = -0.21, p = 0.02; MDD-PRS: β = -0.22, p = 0.01) and more time with any subsyndromal mood symptoms (i.e., any mania, mixed, or depression symptoms; SCZ-PRS: β = 0.15, p = 0.04; MDD-PRS: β = 0.17, p = 0.01) during follow-up. PRSs for BD and ADHD were not significantly associated with any longitudinal mood variable. Conclusions: This exploratory analysis was the first to examine psychiatric PRSs in relation to the prospective course of mood symptoms among youth with BD. Results from the current study can serve to guide future youth BD studies with larger sample sizes on this topic.
期刊介绍:
Journal of Child and Adolescent Psychopharmacology (JCAP) is the premier peer-reviewed journal covering the clinical aspects of treating this patient population with psychotropic medications including side effects and interactions, standard doses, and research on new and existing medications. The Journal includes information on related areas of medical sciences such as advances in developmental pharmacokinetics, developmental neuroscience, metabolism, nutrition, molecular genetics, and more.
Journal of Child and Adolescent Psychopharmacology coverage includes:
New drugs and treatment strategies including the use of psycho-stimulants, selective serotonin reuptake inhibitors, mood stabilizers, and atypical antipsychotics
New developments in the diagnosis and treatment of ADHD, anxiety disorders, schizophrenia, autism spectrum disorders, bipolar disorder, eating disorders, along with other disorders
Reports of common and rare Treatment Emergent Adverse Events (TEAEs) including: hyperprolactinemia, galactorrhea, weight gain/loss, metabolic syndrome, dyslipidemia, switching phenomena, sudden death, and the potential increase of suicide. Outcomes research.